Search Results - "Bucheit, Amanda D."

Emerging insights into resistance to BRAF inhibitors in melanoma by Bucheit, Amanda D., Davies, Michael A.

“…Identification of the multiple mechanisms of resistance to mutant-selective BRAF inhibitors is leading to an improved understanding of the molecular…”
Get full text

Conception and viable twin pregnancy in a patient with metastatic melanoma while treated with CTLA-4 and PD-1 checkpoint inhibition by Bucheit, Amanda D., Hardy, John T., Szender, J. Brian, Glitza Oliva, Isabella C.

“…The treatment of cancer during pregnancy presents a unique challenge. Optimal treatments are often altered or even delayed to protect fetal growth and…”
Get full text

Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma by Bucheit, Amanda D., Syklawer, Erica, Jakob, John A., Bassett, Roland L., Curry, Jonathan L., Gershenwald, Jeffrey E., Kim, Kevin B., Hwu, Patrick, Lazar, Alexander J., Davies, Michael A.

“…BACKGROUND Hotspot mutations in BRAF and NRAS are the most common somatic events in patients with melanoma. These mutations occur at highly conserved residues,…”
Get full text

Melanoma brain metastases harboring BRAF V600K or NRAS mutations are associated with an increased local failure rate following conventional therapy by Fang, Penny, Boehling, Nicholas S, Koay, Eugene J, Bucheit, Amanda D, Jakob, John A, Settle, Stephen H, Brown, Paul D, Davies, Michael A, Sulman, Erik P

“…Studies on melanoma brain metastases (MBM) with regard to mutational status are lacking. We investigated the outcomes of MBM in molecularly characterized…”
Get full text

An oncolytic measles virus engineered to enter cells through the CD20 antigen by Bucheit, Amanda D, Kumar, Shaji, Grote, Deanna M, Lin, Yukang, von Messling, Veronika, Cattaneo, Roberto B, Fielding, Adele K

“…We have earlier shown that attenuated measles virus (MV) has therapeutic potential as a replicating oncolytic virus in models of non-Hodgkin's lymphoma (NHL)…”
Get full text

Melanoma brain metastases harboring BRAFV600K or NRAS mutations are associated with an increased local failure rate following conventional therapy by Fang, Penny, Boehling, Nicholas S., Koay, Eugene J., Bucheit, Amanda D., Jakob, John A., Settle, Stephen H., Brown, Paul D., Davies, Michael A., Sulman, Erik P.

“…Studies on melanoma brain metastases (MBM) with regard to mutational status are lacking. We investigated the outcomes of MBM in molecularly characterized…”
Get full text

Complete Loss of PTEN Protein Expression Correlates with Shorter Time to Brain Metastasis and Survival in Stage IIIB/C Melanoma Patients with BRAF V600 Mutations by Bucheit, Amanda D., Chen, Guo, Siroy, Alan, Tetzlaff, Michael, Broaddus, Russell, Milton, Denai, Fox, Patricia, Bassett, Roland, Hwu, Patrick, Gershenwald, Jeffrey E., Lazar, Alexander J., Davies, Michael A.

“…Purpose: Loss of function of PTEN is a frequent event in melanoma, particularly in tumors with BRAFV600 mutations. The prevalence, pathologic features, and…”
Get full text

Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations by Bucheit, Amanda D, Chen, Guo, Siroy, Alan, Tetzlaff, Michael, Broaddus, Russell, Milton, Denai, Fox, Patricia, Bassett, Roland, Hwu, Patrick, Gershenwald, Jeffrey E, Lazar, Alexander J, Davies, Michael A

“…Loss of function of PTEN is a frequent event in melanoma, particularly in tumors with BRAF(V600) mutations. The prevalence, pathologic features, and clinical…”
Get full text